Jump to content

Page values for "Irbesartan"

"Medicines" values

1 row is stored for this page
FieldField typeValue
genericStringIrbesartan
brandStringAvapro
structureFile
classesList of String, delimiter: ,[[:Category:Angiotensin_receptor_blockers|Angiotensin receptor blocker (ARB)]] [[:Category:Antihypertensives|Antihypertensive]]
mechanismString'"`UNIQ--vote-0000083E-QINU`"' CYP2C9 substrate; no clinically active metabolites. The IDNT trial established renoprotection in diabetic nephropathy independent of BP lowering, contributing to the ARB class indication in T2DM with proteinuria'"`UNIQ--ref-0000083F-QINU`"'.
usesString'"`UNIQ--vote-00000840-QINU`"', '"`UNIQ--vote-00000841-QINU`"'
starting_doseString150 mg PO once daily; titrate to 300 mg if needed
preparationsString75, 150, 300 mg tablets
fda_maxString300 mg/d
pill_idText
routesList of String, delimiter: ,Oral
onsetStringBP effect within 1-2 weeks
durationString24 hours
halflifeString11-15 hours'"`UNIQ--ref-00000842-QINU`"'
bioavailabilityString60-80% (oral; not significantly affected by food)'"`UNIQ--ref-00000843-QINU`"'
pregnancyString'''Contraindicated in pregnancy''' (all trimesters); fetal renal injury, oligohydramnios, hypocalvaria, hypotension. Stop on detection'"`UNIQ--ref-00000844-QINU`"'
legalString[[USLegal:Prescription only|Rx-only]] in US